The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
Open accessAbstract
Background Vaccine effectiveness studies have not differentiated the effect of the delta (B.1.617.2) variant and potential waning immunity in observed reductions in effectiveness against SARS-CoV-2 infections. We aimed to evaluate overall and variant-specific effectiveness of BNT162b2 (tozinameran, Pfizer-BioNTech) against SARS-CoV-2 infections and COVID-19-related hospital admissions by time since vaccination among members of a large US health-care system. Methods In this retrospective cohort study, we analysed electronic health records of individuals (≥12 years) who were members of the health-care organisation Kaiser Permanente Southern California (CA, USA), to assess BNT162b2 vaccine effectiveness against SARS-CoV-2 infections and COVID-19-related hospital admissions for up to 6 months. Participants were required to have 1 year or more previous membership of the organisation. Outcomes comprised SARS-CoV-2 PCR-positive tests and COVID-19-related hospital admissions. Effectiveness calculations were based on hazard ratios from adjusted Cox models. This study was registered with ClinicalTrials.gov, NCT04848584. Findings Between Dec 14, 2020, and Aug 8, 2021, of 4 920 549 individuals assessed for eligibility, we included 3 436 957 (median age 45 years [IQR 29-61]; 1 799 395 [52·4%] female and 1 637 394 [47·6%] male). For fully vaccinated individuals, effectiveness against SARS-CoV-2 infections was 73% (95% CI 72-74) and against COVID-19-related hospital admissions was 90% (89-92). Effectiveness against infections declined from 88% (95% CI 86-89) during the first month after full vaccination to 47% (43-51) after 5 months. Among sequenced infections, vaccine effectiveness against infections of the delta variant was high during the first month after full vaccination (93% [95% CI 85-97]) but declined to 53% [39-65] after 4 months. Effectiveness against other (non-delta) variants the first month after full vaccination was also high at 97% (95% CI 95-99), but waned to 67% (45-80) at 4-5 months. Vaccine effectiveness against hospital admissions for infections with the delta variant for all ages was high overall (93% [95% CI 84-96]) up to 6 months. Interpretation Our results provide support for high effectiveness of BNT162b2 against hospital admissions up until around 6 months after being fully vaccinated, even in the face of widespread dissemination of the delta variant. Reduction in vaccine effectiveness against SARS-CoV-2 infections over time is probably primarily due to waning immunity with time rather than the delta variant escaping vaccine protection. Funding Pfizer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several studies have described a drop over time of two-dose vaccine effectiveness against SARS-CoV-2 symptomatic infection;”
From Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France (2023) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“this decrease in protection was substantially higher against Omicron BA.1 compared to Delta [3,8,12,19,26].”
From Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France (2023) · cites this paper as [8]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Real-world setting studies performed, few months into vaccination campaigns, showed high effectiveness of these vaccines [1-8].”
The cited source says what the claim attributes to it.
In the citing paper
“However, as vaccination campaigns progressed, additional vaccine effectiveness (VE) studies revealed waning of the vaccine-induced protection over time [8-13]”
In the citing paper
“Yet, vaccine-induced immunity remains effective at preventing severe disease, hospitalization, and death, even at later time points when antibody levels may have declined (10–12).”
From mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern (2021) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · doi:10.1101/2021.07.28.21261159 · Cited by 1,640
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110345 · Cited by 1,640
Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00947-8 · Cited by 1,564
Self-citationLopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389
The Development of a Standardized Neighborhood Deprivation Index
Messer, L. C., Laraia, B. A., Kaufman, J. S., Eyster, J. T., Holzman, C., Culhane, J. F., Elo, I. T., Burke, J. G., & O'Campo, P. J. (2006) · Journal of Urban Health · doi:10.1007/s11524-006-9094-x · Cited by 1,046
Sheikh, A., McMenamin, J., Taylor, B., & Robertson, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01358-1 · Cited by 939
Research works printed but not linked: 1
- Lopez Bernal, 2021, Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant, N Engl J Med, 385, 585, 10.1056/NEJMoa2108891 · DOI · Paper page
Cited by
Sorted by citations
Items 201–300 of 1,001
A Mini Review on SARS-COVID-19-2 Omicron Variant (B.1.1.529)
Ettaboina, S. K., Nakkala, K., & Laddha, K. S. (2021) · SciMedicine Journal · doi:10.28991/scimedj-2021-0304-10 · Cited by 32
Malden, D. E., Liu, I. A., Qian, L., Sy, L. S., Lewin, B. J., Asamura, D. T., Ryan, D. S., Bezi, C., Williams, J. T. B., Kaiser, R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48022-9 · Cited by 32
Self-citationChadeau‐Hyam, M., Wang, H., Eales, O. D., Haw, D., Bodinier, B., Whitaker, M. D., Walters, C. E., Ainslie, K. E. C., Atchison, C. J., Fronterrè, C., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101419 · Cited by 29
Impact of national Covid-19 vaccination Campaign, South Korea
Yi, S., Choe, Y. J., Lim, D. S., Lee, H. R., Kim, J., Kim, Y.-Y., Kim, R. K., Jang, E. J., Lee, S., Park, E.-J., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.05.002 · Cited by 32
Xu, K., Fan, C., Han, Y., Dai, L., & Gao, G. F. (2022) · International Immunology · doi:10.1093/intimm/dxac031 · Cited by 31
Waning immunity to SARS-CoV-2 following vaccination or infection
Hernández-Suárez, C., & Murillo‐Zamora, E. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.972083 · Cited by 31
The vaccine hesitancy continuum among hesitant adopters of the COVID‐19 vaccine
Moore, R. A., Purvis, R. S., Willis, D. E., Worley, K. C., Hervey, D., Reece, S., Yeates, A., & McElfish, P. A. (2022) · Clinical and Translational Science · doi:10.1111/cts.13385 · Cited by 32
Archambault, P. M., Rosychuk, R. J., Audet, M., Bola, R., Vatanpour, S., Brooks, S. C., Daoust, R., Clark, G., Grant, L., Vaillancourt, S., et al. (2023) · JMIR Public Health and Surveillance · doi:10.2196/44465 · Cited by 31
β-Glucans Could Be Adjuvants for SARS-CoV-2 Virus Vaccines (COVID-19)
Córdova, A., Caballero-García, A., Roche, E., & Noriega, D. C. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182312636 · Cited by 33
Herzberg, J., Fischer, B., Lindenkamp, C., Becher, H., Becker, A., Honarpisheh, H., Guraya, S. Y., Strate, T. G., & Knabbe, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.839922 · Cited by 30
COVID-19 forecasting using new viral variants and vaccination effectiveness models
Rashed, E. A., Kodera, S., & Hirata, A. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105986 · Cited by 31
Feng, A., Obolski, U., Stone, L., & He, D. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0001211 · Cited by 30
Bouillon, K., Baricault, B., Botton, J., Jabagi, M.-J., Bertrand, M., Semenzato, L., Le Vu, S., Drouin, J., Dray-Spira, R., Weill, A., et al. (2022) · BMJ Medicine · doi:10.1136/bmjmed-2021-000104 · Cited by 31
Ferreira, I. A. T. M., Lee, C. Y. C., Foster, W. S., Abdullahi, A., Dratva, L. M., Tuong, Z. K., Stewart, B. J., Ferdinand, J. R., Guillaume, S. M., Potts, M., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112991 · Cited by 30
Freund, O., Tau, L., Weiss, T. E., Zornitzki, L., Frydman, S., Jacob, G., & Bornstein, G. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268050 · Cited by 31
Tong, K. K., He, M., Wu, A. M. S., Dang, L., & Chen, J. H. (2021) · Vaccines · doi:10.3390/vaccines9101170 · Cited by 28
Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection
Puranik, A., Lenehan, P. J., Silvert, E., Niesen, M. J. M., Corchado-García, J., O’Horo, J. C., Virk, A., Swift, M. D., Gordon, J. E., Speicher, L. L., et al. (2021) · Med · doi:10.1016/j.medj.2021.12.002 · Cited by 31
Oroszi, B., Juhász, A., Nagy, C., Horváth, J. K., Komlos, K., Túri, G., McKee, M., & Ádány, R. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030388 · Cited by 33
Kodera, S., Rashed, E. A., & Hirata, A. (2022) · Vaccines · doi:10.3390/vaccines10030430 · Cited by 28
Nishimi, K. M., Neylan, T. C., Bertenthal, D., Seal, K. H., & O’Donovan, A. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.7287 · Cited by 30
Adachi, M., Murakami, M., Yoneoka, D., Kawashima, T., Hashizume, M., Sakamoto, H., Eguchi, A., Ghaznavi, C., Gilmour, S., Kaneko, S., et al. (2022) · SSM - Population Health · doi:10.1016/j.ssmph.2022.101105 · Cited by 32
Rennert, L., Ma, Z., McMahan, C. S., & Dean, D. (2022) · Nature Communications · doi:10.1038/s41467-022-31469-z · Cited by 31
COVID‐19: Clinical status of vaccine development to date
Kumar, S., Basu, M., Ghosh, P., Ansari, A., & Ghosh, M. K. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15552 · Cited by 32
Kayano, T., Ko, Y., Otani, K., Kobayashi, T., Suzuki, M., & Nishiura, H. (2023) · Scientific Reports · doi:10.1038/s41598-023-44942-6 · Cited by 31
Rahman, M. O., Kamigaki, T., Thandar, M. M., Haruyama, R., Yan, F., Shibamura-Fujiogi, M., Khin Maung Soe, J., Islam, M. R., Yoneoka, D., Miyahara, R., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-076892 · Cited by 29
Cardiovascular Complications of COVID-19 Vaccines
Liu, R., Pan, J., Zhang, C., & Sun, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.840929 · Cited by 28
Humoral Response to BNT162b2 Vaccine Against SARS-CoV-2 Variants Decays After Six Months
Lopera, T. J., Chvatal‐Medina, M., Flórez‐Álvarez, L., Zapata-Cardona, M. I., Taborda, N. A., Rugeles, M. T., & Hernández, J. C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.879036 · Cited by 29
Huang, Z., Xu, S., Liu, J., Wu, L., Qiu, J., Wang, N., Ren, J., Li, Z., Guo, X., Tao, F., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37673-9 · Cited by 29
Vaccination is the most effective and best way to avoid the disease of COVID‐19
Lotfi, H., Mazar, M. G., Ei, N. M. H., Fahim, M., & Yazdi, N. S. (2023) · Immunity Inflammation and Disease · doi:10.1002/iid3.946 · Cited by 33
Tcheou, J., Raskin, A. J., Singh, G., Kawabata, H., Bielak, D. A., Sun, W., González‐Domínguez, I., Sather, D. N., García‐Sastre, A., Palese, P., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.791764 · Cited by 28
Botton, J., Dray‐Spira, R., Baricault, B., Drouin, J., Bertrand, M., Jabagi, M.-J., Weill, A., & Zureik, M. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.12.009 · Cited by 28
Yonker, L. M., Swank, Z., Gilboa, T., Senussi, Y., Kenyon, V., Papadakis, L., Boribong, B. P., Carroll, R. W., Walt, D. R., & Fasano, A. (2022) · Critical Care Explorations · doi:10.1097/cce.0000000000000641 · Cited by 29
Mousa, M., Albreiki, M. S., Alshehhi, F., AlShamsi, S., Marzouqi, N. A., Alawadi, T., Alrand, H., AlSafar, H. S., & Fikri, A. (2022) · Journal of Travel Medicine · doi:10.1093/jtm/taac036 · Cited by 29
Martellucci, C. A., Flacco, M. E., Soldato, G., Martino, G. D., Carota, R., Caponetti, A., & Manzoli, L. (2022) · Vaccines · doi:10.3390/vaccines10050662 · Cited by 29
Syversen, S. W., Jyssum, I., Tveter, A. T., Sexton, J., Christensen, I. E., Tran, T. T., Bjørlykke, K. H., Mjaaland, S., Warren, D. J., Kvien, T. K., et al. (2022) · RMD Open · doi:10.1136/rmdopen-2022-002417 · Cited by 29
COVID-19 Vaccines over Three Years after the Outbreak of the COVID-19 Epidemic
Zasada, A. A., Darlińska, A., Wiatrzyk, A., Woźnica, K., Formińska, K., Czajka, U., Główka, M., Lis, K., & Górska, P. (2023) · Viruses · doi:10.3390/v15091786 · Cited by 29
Andrejko, K. L., Pry, J. M., Myers, J. F., Mehrotra, M., Lamba, K., Lim, E., Fukui, N., DeGuzman, J. L., Openshaw, J., Watt, J., et al. (2023) · American Journal of Epidemiology · doi:10.1093/aje/kwad017 · Cited by 28
Nakahara, T., Iwabuchi, Y., Miyazawa, R., Tonda, K., Shiga, T., Strausś, H. W., Antoniades, C. A., Narula, J., & Jinzaki, M. (2023) · Radiology · doi:10.1148/radiol.230743 · Cited by 28
Recent Advances in Delivery Systems for Genetic and Other Novel Vaccines
Huang, S., Zhu, Y., Zhang, L., & Zhang, Z. (2021) · Advanced Materials · doi:10.1002/adma.202107946 · Cited by 28
Tan, S. H. X., Pung, R., Wang, L., Lye, D. C., Ong, B. K. C., Cook, A. R., & Tan, K. B. (2022) · JAMA · doi:10.1001/jama.2022.1922 · Cited by 26
Micronutrients to Support Vaccine Immunogenicity and Efficacy
Calder, P. C., Berger, M. M., Gombart, A. F., McComsey, G. A., Martineau, A. R., & Eggersdorfer, M. L. (2022) · Vaccines · doi:10.3390/vaccines10040568 · Cited by 27
COVID-19 Vaccines' Protection Over Time and the Need for Booster Doses; a Systematic Review.
Dadras, O., SeyedAlinaghi, S., Karimi, A., Shojaei, A., Amiri, A., Mahdiabadi, S., Fakhfouri, A., Razi, A., Mojdeganlou, H., Mojdeganlou, P., et al. (2022) · Archives of Academic Emergency Medicine · doi:10.22037/aaem.v10i1.1582 · Cited by 28
Chiew, C. J., Premikha, M., Chong, C. Y., Wei, W. E., Ong, B. K. C., Lye, D. C., Heng, D., Lee, V. J., & Tan, K. B. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00573-4 · Cited by 28
Tamandjou Tchuem, C. R., Auvigne, V., Vaux, S., Montagnat, C., Paireau, J., Monnier Besnard, S., Gabet, A., Benhajkassen, N., Le Strat, Y., Parent Du Chatelet, I., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.02.062 · Cited by 27
Gharpure, R. V., Sami, S., Vostok, J., Johnson, H., Hall, N. B., Foreman, A., Sabo, R. T., Schubert, P. L., Shephard, H. M., Brown, V. R., et al. (2021) · Emerging infectious diseases · doi:10.3201/eid2801.212220 · Cited by 27
Bosetti, P., Kiem, C. T., Andronico, A., Paireau, J., Lévy-Bruhl, D., Alter, L., Fontanet, A. L., & Cauchemez, S. (2022) · Eurosurveillance · doi:10.2807/1560-7917.es.2022.27.1.2101125 · Cited by 27
COVID-19 Vaccination Should not be Mandatory for Health and Social Care Workers
Rodger, D., & Blackshaw, B. P. (2022) · The New Bioethics · doi:10.1080/20502877.2022.2025651 · Cited by 26
Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222
Terpos, E., Karalis, V. D., Ntanasis‐Stathopoulos, I., Evangelakou, Z., Gavriatopoulou, M., Manola, M. S., Malandrakis, P., Gianniou, D. D., Kastritis, E., Trougakos, I. P., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10020338 · Cited by 25
Modeling Vaccine Efficacy for COVID-19 Outbreak in New York City
Jacques Demongeot, A., Griette, Q., Magal, P., & Webb, G. F. (2022) · Biology · doi:10.3390/biology11030345 · Cited by 28
A Cost–Benefit Analysis of COVID-19 Vaccination in Catalonia
Seguí, F. L., Català, M., Prats, C., Estrada, O., Oliva, I., Prat, N., Isnard, M., Vallès, R., Vilar, M., Clotet, B., et al. (2021) · Vaccines · doi:10.3390/vaccines10010059 · Cited by 27
Yang, S. L., Ripen, A. M., Leong, C. T., Lee, J. V., Yen, C. H., Chand, A. K., Koh, K., Rahim, N. A. B. A., Gokilavanan, V., Mohamed, N. N. E., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2065936 · Cited by 28
COVID-19 Vaccination and Estimated Public Health Impact in California
Tan, S. T., Park, H. J., Rodríguez-Barraquer, I., Rutherford, G. W., Bibbins-Domingo, K. B., Schechter, R., & Lo, N. C. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.8526 · Cited by 26
Impact of SARS‐CoV‐2 infection on vaccine‐induced immune responses over time
Havervall, S., Marking, U. W., Greilert‐Norin, N., Gordon, M., Ng, H., Christ, W., Phillipson, M., Nilsson, P., Hober, S., Blom, K. G., et al. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1388 · Cited by 24
Strength and durability of antibody responses to BNT162b2 and CoronaVac
Cowling, B. J., Wong, I. O. L., Shiu, E. Y. C., Lai, A. Y. T., Cheng, S. M. S., Chaothai, S., Kwan, K. K. H., Martín-Sánchez, M., Poon, L. L. M., Ip, D., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.05.033 · Cited by 26
Ouyang, W. O., Tan, T. J. C., Lei, R., Song, G., Kieffer, C., Andrabi, R., Matreyek, K. A., & Wu, N. C. (2022) · Science Advances · doi:10.1126/sciadv.add7221 · Cited by 27
Fong, C. H.-Y., Zhang, X., Chen, L., Poon, R. W., Chan, B. P.-C., Zhao, Y., Wong, C. K. H., Chan, K., Yuen, K., Hung, I. F., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104446 · Cited by 27
Why promoting a COVID-19 vaccine booster dose?
Loubet, P., Laureillard, D., Martin, A., Larcher, R., & Sotto, A. (2021) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2021.100967 · Cited by 27
Passport to neoliberal normality? A critical exploration of COVID-19 vaccine passports.
Telford, L., Bushell, M., & Hodgkinson, O. (2022) · Journal of Contemporary Crime Harm and Ethics · doi:10.19164/jcche.v2i1.1224 · Cited by 26
Bosetti, P., Kiem, C. T., Andronico, A., Vittoria Colizza, A., Yazdanpanah, Y., Fontanet, A. L., Benamouzig, D., & Cauchemez, S. (2022) · BMC Medicine · doi:10.1186/s12916-022-02235-1 · Cited by 24
Rapid antigen testing as a reactive response to surges in nosocomial SARS-CoV-2 outbreak risk
Smith, D. R., Duval, A., Zahar, J., the EMAE-MESuRS Working Group on Nosocomial SARS-CoV-2 Modelling, Hendrickx, N., Jean, K., Jijón, S., Oodally, A., Shirreff, G., Tamandjou, C. R. T., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27845-w · Cited by 28
Choi, J. H., Kim, Y. R., Heo, S. T., Oh, H., Kim, M.-S., Lee, H. R., & Yoo, J. R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.827306 · Cited by 26
Gao, P., Cai, S., Liu, Q., Du, M., Liu, J., & Liu, M. (2022) · Vaccines · doi:10.3390/vaccines10030421 · Cited by 26
Gao, P., Kang, L., Liu, J., & Liu, M. (2023) · World Journal of Pediatrics · doi:10.1007/s12519-022-00680-9 · Cited by 25
SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines
Sunagar, R., Singh, A., & Kumar, S. (2023) · Vaccines · doi:10.3390/vaccines11040849 · Cited by 31
Protection by vaccines and previous infection against the Omicron variant of SARS-CoV-2
Šmíd, M., Berec, L., Májek, O., Pavlík, T., Jarkovský, J., Weiner, J., Přibylová, L., Barusová, T., & Trnka, J. (2022) · doi:10.1101/2022.02.24.22271396 · Cited by 67
Dallan, B., Proietto, D., Laurentis, M. D., Gallerani, E., Martino, M., Ghisellini, S., Zurlo, A., Volpato, S., Govoni, B., Borghesi, M., et al. (2024) · Nature Aging · doi:10.1038/s43587-024-00644-w · Cited by 30
Leekha, A., Saeedi, A., Sefat, K. M. S. R., Kumar, M., Martinez-Paniagua, M. A., Damian, A., Kulkarni, R. S., Reichel, K., Rezvan, A., Masoumi, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50133-2 · Cited by 25
Loconsole, D., Centrone, F., Morcavallo, C., Campanella, S., Accogli, M., Sallustio, A., Peccarisi, D., Stufano, A., Lovreglio, P., & Chironna, M. (2021) · Vaccines · doi:10.3390/vaccines9111354 · Cited by 27
Saied, A. A., Metwally, A. A., Alobo, M., Shah, J., Sharun, K., & Dhama, K. (2022) · International Journal of Surgery · doi:10.1016/j.ijsu.2022.106233 · Cited by 25
Hahn, W. O., & Wiley, Z. (2022) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2022.01.008 · Cited by 27
Siller, A., Seekircher, L., Wachter, G. A., Astl, M., Tschiderer, L., Pfeifer, B. E., Gaber, M., Schennach, H., & Willeit, P. (2022) · Viruses · doi:10.3390/v14030568 · Cited by 24
Lü, Y., Tang, L., Zhang, M., & Liu, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.896958 · Cited by 28
Human coronaviruses: The emergence of SARS-CoV-2 and management of COVID-19
Solomon, M., & Liang, C. (2022) · Virus Research · doi:10.1016/j.virusres.2022.198882 · Cited by 25
Vaccines against SARS-CoV-2 variants and future pandemics
Park, T., Hwang, H., Moon, S., Kang, S. G., Song, S., Kim, Y. H., Kim, H., Ko, E., Yoon, S., Kang, S., et al. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2110075 · Cited by 23
van den Hoogen, L. L., Boer, M. C., Postema, A., de Rond, L., de Zeeuw‐Brouwer, M., Pronk, I., Wijmenga‐Monsuur, A. J., Bijvank, E., Kruiper, C., Beckers, L., et al. (2022) · Vaccines · doi:10.3390/vaccines10091480 · Cited by 25
Razonable, R. R., Tulledge‐Scheitel, S. M., Hanson, S. N., Arndt, R. F., Speicher, L. L., Seville, T. A., Larsen, J. J., Ganesh, R., & O’Horo, J. C. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac411 · Cited by 25
Sabu, J. M., Zahid, I., Jacob, N., Alele, F. O., & Malau‐Aduli, B. S. (2022) · Vaccines · doi:10.3390/vaccines10111880 · Cited by 24
Immunoglobulins response of COVID-19 patients, COVID-19 vaccine recipients, and random individuals
Al‐Tamimi, M., Tarifi, A. A., Qaqish, A., Abbas, M. M., Albalawi, H., Abu-Raideh, J. A., Salameh, M. A., & Khasawneh, A. I. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281689 · Cited by 25
Vaccine hesitancy in cancer patients: A rapid review
Butow, P. N., Shaw, J., Bartley, N., Milch, V., Sathiaraj, R., Turnbull, S., & Vartanian, C. D. (2023) · Patient Education and Counseling · doi:10.1016/j.pec.2023.107680 · Cited by 28
Calabrò, G. E., Pappalardo, C., D’Ambrosio, F., Vece, M., Lupi, C., Lontano, A., Russo, M. D., Ricciardi, R., & de Waure, C. (2023) · Vaccines · doi:10.3390/vaccines11051011 · Cited by 27
Giardina, J., Bilinski, A., Fitzpatrick, M. C., Kendall, E. A., Linas, B. P., Salomon, J. A., & Ciaranello, A. L. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.47827 · Cited by 24
Modelling the COVID-19 epidemic and the vaccination campaign in Italy by the SUIHTER model
Parolini, N., Dede’, L., Ardenghi, G., & Quarteroni, A. M. (2022) · Infectious Disease Modelling · doi:10.1016/j.idm.2022.03.002 · Cited by 29
Kissling, E., Hooiveld, M., Martínez‐Baz, I., Mazagatos, C., William, N., Vilcu, A., Kooijman, M. N., Ilić, M., Domegan, L. M., Machado, A., et al. (2022) · Eurosurveillance · doi:10.2807/1560-7917.es.2022.27.21.2101104 · Cited by 25
Individual-level social capital and COVID-19 vaccine hesitancy in Japan: a cross-sectional study
Machida, M., Kikuchi, H., Kojima, T., Nakamura, I., Saito, R., Nakaya, T., Hanibuchi, T., Takamiya, T., Odagiri, Y., Fukushima, N., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2086773 · Cited by 23
Tartof, S. Y., Frankland, T. B., Slezak, J. M., Puzniak, L., Hong, V. X., Xie, F., Ackerson, B. K., Valluri, S. R., Jódar, L., & McLaughlin, J. M. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.25162 · Cited by 24
Self-citationOgden, N. H., Turgeon, P., Fazil, A., Clark, J., Gabriele-Rivet, V., Tam, T. W. S., & Ng, V. (2022) · Canada Communicable Disease Report · doi:10.14745/ccdr.v48i78a01 · Cited by 24
Nasreen, S., Febriani, Y., García, H. A. V., Zhang, G., Tadrous, M., Buchan, S. A., Righolt, C. H., Mahmud, S. M., Janjua, N. Z., Krajden, M., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac634 · Cited by 23
Meyers, J., Windau, A., Schmotzer, C. L., Saade, E., Noguez, J. H., Stempak, L. M., & Zhang, X. S. (2022) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2022.115803 · Cited by 24
Ailsworth, S. M., Keshavarz, B., Richards, N. E., Workman, L. J., Murphy, D. D., Nelson, M. R., Platts‐Mills, T. A. E., & Wilson, J. M. (2022) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2022.10.003 · Cited by 24
Bello‐Chavolla, O. Y., Antonio‐Villa, N. E., Valdés‐Ferrer, S. I., Fermín‐Martínez, C. A., Fernández‐Chirino, L., Vargas‐Vázquez, A., Ramírez‐García, D., Mancilla-Galindo, J., Kammar‐García, A., Ávila‐Funes, J. A., et al. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.01.040 · Cited by 32
Veneti, L., Berild, J. D., Watle, S. V., Starrfelt, J., Greve‐Isdahl, M., Langlete, P., Bøås, H., Bragstad, K., Hungnes, O., & Meijerink, H. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.03.004 · Cited by 34
Uwamino, Y., Kurafuji, T., Takato, K., Sakai, A., Tanabe, A., Noguchi, M., Yatabe, Y., Arai, T., Ohno, A., Tomita, Y., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.06.016 · Cited by 21
Zhang, R., Khong, K.-W., Leung, K., Liu, D., Fan, Y., Lu, L., Chan, P.-C., Chen, L., To, K. K., Chen, H., et al. (2021) · Vaccines · doi:10.3390/vaccines9121442 · Cited by 24
Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine
Gandolfo, C., Anichini, G., Mugnaini, M., Bocchia, M., Terrosi, C., Sicuranza, A., Savellini, G. G., Gozzetti, A., Franchi, F., & Cusi, M. G. (2022) · Vaccines · doi:10.3390/vaccines10020171 · Cited by 23
Trends in COVID-19 Vaccine Administration and Effectiveness Through October 2021
Winkelman, T. N. A., Rai, N. K., Bodurtha, P. J., Chamberlain, A. M., DeSilva, M. B., Jeruzal, J. N., Johnson, S., Kharbanda, A. B., Klyn, N. A. M., Mink, P. J., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.5018 · Cited by 24
Giménez, E., Albert, E., Zulaica, J., Torres, I., Rusu, L., Rodríguez-Moreno, A., Burgos, J. S., Peiró, S., Salas, D., Vanaclocha, H., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac223 · Cited by 22
Smolenov, I. V., Han, H. H., Li, P., Baccarini, C. I., Verhoeven, C., Rockhold, F. W., Clemens, S. A. C., Ambrosino, D. M., Richmond, P., Siber, G. R., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00144-x · Cited by 23
Rzymski, P., Pazgan−Simon, M., Kamerys, J., Moniuszko-Malinowska, A. M., Sikorska, K., Wernik, J., Zarębska‐Michaluk, D., Supronowicz, Ł., Sobala‐Szczygieł, B., Skrzat‐Klapaczyńska, A., et al. (2022) · Vaccines · doi:10.3390/vaccines10040557 · Cited by 23
Impact of prior vaccination on clinical outcomes of patients with COVID-19
Seo, W. J., Kang, J., Kang, H. K., Park, S. H., Koo, H., Park, H. K., Lee, S.-S., Song, J. E., Kwak, Y. G., & Kang, J. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2069516 · Cited by 22
Maeda, H., Saito, N., Igarashi, A., Ishida, M., Suami, K., Yagiuchi, A., Kimura, Y., Komino, M., Arai, H., Morikawa, T., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac292 · Cited by 23
Metadata
- Authors
- Tartof, S. Y., Slezak, J. M., Fischer, H., Hong, V., Ackerson, B. K., Ranasinghe, O. N., Frankland, T. B., Ogun, O. A., Zamparo, J. M., Gray, S., Valluri, S. R., Pan, K., Angulo, F. J., Jodar, L., & McLaughlin, J. M.
- Affiliations
- Kaiser Permanente (US)
- Pfizer (United States) (US)
- Corresponding author
- Tartof, Sara Y
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2021-10
- Volume
- 398
- Issue
- 10309
- Pages
- 1407-1416
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC8489881
- OpenAlex
- W3202826390
- Cited by
- 1,167
- References
- 37
- Citations by year
- 2026: 33 · 2025: 70 · 2024: 116 · 2023: 257 · 2022: 583 · 2021: 108
- FWCI
- 84.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer Inc Boulder
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Keywords
- BNT162b2, COVID-19 vaccines, mRNA vaccines, vaccine effectiveness, COVID-19 pandemic, COVID-19 hospitalization, Delta variant, waning immunity, integrated health system, Kaiser Permanente, time since vaccination, SARS-CoV-2 sequencing
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Aged, 80 and over, Child, Female, Hospitalization, Humans, Male, Middle Aged, Organizations, Retrospective Studies, RNA, Messenger, Time Factors, United States, Vaccination, Delivery of Health Care, Integrated
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
